{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:06:27Z","timestamp":1778288787061,"version":"3.51.4"},"reference-count":60,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jval.2017.05.013","type":"journal-article","created":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T14:16:01Z","timestamp":1498054561000},"page":"1260-1269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril\/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines"],"prefix":"10.1016","volume":"20","author":[{"given":"Isaac Corro","family":"Ramos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthijs M.","family":"Versteegh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanda M.A.","family":"Koenders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard C.M.","family":"Linssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan G.","family":"Meeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen P.M.H.","family":"Rutten-van M\u00f6lken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2017.05.013_bib1","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jval.2017.05.013_bib2","first-page":"282","volume":"134","author":"Yancy","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jval.2017.05.013_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1524-4733.2008.00425.x","article-title":"Utility estimates for decision-analytic modeling in chronic heart failure--health states based on New York Heart Association classes and number of rehospitalizations","volume":"12","author":"Gohler","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2017.05.013_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2010.165","article-title":"Epidemiology and risk profile of heart failure","volume":"8","author":"Bui","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jval.2017.05.013_bib5","unstructured":"Dutch national public health and health care (Volksgezondheidenzorg.info) prevalence and incidence figures [in Dutch]. Available from: https:\/\/www.volksgezondheidenzorg.info\/onderwerp\/hartfalen\/cijfers-context\/prevalentie-en-incidentie#!node-aantal-mensen-met-hartfalen. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib6","unstructured":"The Netherlands Society of Cardiology (Nederlandse Vereniging voor Cardiologie). Multidisciplinary heart failure guidelines (Multidisciplinaire richtlijn Hartfalen \u2013 in Dutch). Available from: https:\/\/www.nvvc.nl\/richtlijnen\/bestaande-richtlijnen#hartfalen. [Accessed November 19, 2016]."},{"issue":"9851","key":"10.1016\/j.jval.2017.05.013_bib7","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor ARNi in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2017.05.013_bib8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jval.2017.05.013_bib9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2017.05.013_bib10","series-title":"A new cost-effectiveness modelling approach in chronic heart failure with reduced ejection fraction","author":"McMurray","year":"2015"},{"key":"10.1016\/j.jval.2017.05.013_bib11","unstructured":"The National Health Care Institute (Zorginstituut Nederland). Guideline for economic evaluations in healthcare. Available from: https:\/\/www.zorginstituutnederland.nl\/binaries\/content\/documents\/zinl-www\/documenten\/publicaties\/publications-in-english\/2016\/1606-guideline-for-economic-evaluations-in-healthcare\/Guideline+for+economic+evaluations+in+healthcare.pdf. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib12","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s40273-016-0431-y","article-title":"From good to better: new Dutch guidelines for economic evaluations in health care","volume":"34","author":"Versteegh","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2017.05.013_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0167-6296(98)00039-3","article-title":"The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies","volume":"18","author":"Claxton","year":"1999","journal-title":"J Health Econ"},{"key":"10.1016\/j.jval.2017.05.013_bib14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0140-6736(02)09832-X","article-title":"A rational framework for decision making by the National Institute for Clinical Excellence (NICE)","volume":"360","author":"Claxton","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2017.05.013_bib15","series-title":"Decision Modelling for Health Economic Evaluation","article-title":"Decision making, uncertainty and the value of information","author":"Claxton","year":"2006"},{"key":"10.1016\/j.jval.2017.05.013_bib16","unstructured":"The National Health Care Institute (Zorginstituut Nederland). Sacubitril\/valsartan (Entresto\u00ae) Medicines Reimbursement System (GVS) assessment dossier [in Dutch]. Available from: https:\/\/www.zorginstituutnederland.nl\/binaries\/content\/documents\/zinl-www\/documenten\/publicaties\/geneesmiddelbeoordelingen\/2016\/1604-sacubitril-valsartan-entresto\/1604-sacubitril-valsartan-entresto\/sacubitril-valsartan+%28Entresto%29.pdf. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib17","unstructured":"Dutch government website (overheid.nl). Regulation of the Minister of Health, Welfare and Sport of June 14, 2016 [in Dutch]. Available from: https:\/\/zoek.officielebekendmakingen.nl\/stcrt-2016-32187.html. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib18","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1053\/euhj.2000.2533","article-title":"The prognosis of heart failure in the general population: the Rotterdam Study","volume":"22","author":"Mosterd","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jval.2017.05.013_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jval.2017.05.013_bib20","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2017.05.013_bib21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2017.05.013_bib22","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2017.05.013_bib23","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S0735-1097(16)31303-1","article-title":"A cost-effectiveness analysis in the US of LCZ696 (sacubitril\/valsartan) versus renin-angiotensin-aldosterone system inhibition for heart failure patients with reduced ejection fraction","volume":"67","author":"Gaziano","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jval.2017.05.013_bib24","unstructured":"The National Health Care Institute (Zorginstituut Nederland). Cost-effectiveness in practice [in Dutch]. Available from: https:\/\/www.zorginstituutnederland.nl\/actueel\/nieuws\/2015\/zorginstituut-stelt-rapport-%E2%80%98kosteneffectiviteit-in-de-praktijk%E2%80%99-vast.html. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib25","unstructured":"Institute for Medical Technology Assessment. The iMTA Disease Burden Calculator (iDBC) for proportional shortfall and fair innings for The Netherlands. Available from: www.imta.nl\/idbc. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib26","unstructured":"Statistics Netherlands (CBS). Population life expectancy [in Dutch]. Available from: https:\/\/www.cbs.nl\/nl-nl\/visualisaties\/resterende--gezonde---levensverwachting. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-9-17","article-title":"Decomposing cross-country differences in quality adjusted life expectancy: the impact of value sets","volume":"9","author":"Heijink","year":"2011","journal-title":"Popul health Metr"},{"key":"10.1016\/j.jval.2017.05.013_bib28","unstructured":"Statistics Netherlands (CBS). Employment: key figures [in Dutch]. Available from: http:\/\/statline.cbs.nl\/StatWeb\/publication\/?VW=T&DM=SLNL&PA=82309NED&LA=NL. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cardfail.2011.12.007","article-title":"Association between prehospital delay and subsequent clinical course in patients with\/hospitalized for heart failure","volume":"18","author":"Johansson","year":"2012","journal-title":"J Card Fail"},{"key":"10.1016\/j.jval.2017.05.013_bib30","first-page":"367","article-title":"Guide to cost research\u2014methods and standard costing for economic evaluations in health care [in Dutch]","volume":"90","author":"Hakkaart-van","year":"2012","journal-title":"Tijds Gezondheids Wetenschappen"},{"key":"10.1016\/j.jval.2017.05.013_bib31","unstructured":"The National Health Care Institute (Zorginstituut Nederland). Ivabradine (Procoralan) Medicines Reimbursement System (GVS) assessment dossier [in Dutch]. Available from: https:\/\/www.zorginstituutnederland.nl\/binaries\/content\/documents\/zinl-www\/documenten\/publicaties\/geneesmiddelbeoordelingen\/2013\/1303-ivabradine-procoralan\/1303-ivabradine-procoralan\/ivabradine+%28Procoralan%29.pdf. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib32","unstructured":"National Institute for Public Health and Environment (RIVM). Informal Care: What Does It Cost and Who Pays for It? [in Dutch]. Bilthoven, the Netherlands: RIVM, 2001 Report."},{"key":"10.1016\/j.jval.2017.05.013_bib33","unstructured":"Z-index. Dutch drug database [in Dutch]. Available from: https:\/\/www.z-index.nl. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib34","unstructured":"The Effective Cardio project participants. The path to sustainable heart-failure care [in Dutch]. Available from: http:\/\/nieuws.achmea.nl\/download\/81234\/20141114rapporteffectivecardio_eenpraktijkonderzoeknaaroptimalisatievanhetzorgpadchronischhartfalen.pdf. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/eurjhf\/hfq221","article-title":"European Society of Cardiology Heart Failure Association Standards for delivering heart failure care","volume":"13","author":"McDonagh","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jval.2017.05.013_bib36","unstructured":"The Dutch Healthcare Authority (Nederlandse Zorgautoriteit). Diagnosis and treatment combinations (DBC) fees for healthcare products [in Dutch]. Available from: http:\/\/dbc-zorgproducten-tarieven.nza.nl\/nzaZpTarief\/Welkom.aspx. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib37","first-page":"1574","article-title":"Kwaliteit van leven meten in economische evaluaties: het Nederlands EQ-5D-tarief","volume":"149","author":"Lamers","year":"2005","journal-title":"Ned TijdschrGeneeskd"},{"key":"10.1016\/j.jval.2017.05.013_bib38","unstructured":"Statistics Netherlands (CBS). Population mortality [in Dutch]. Available from: http:\/\/statline.cbs.nl\/StatWeb\/publication\/?VW=T&DM=SLNL&PA=7052_95&LA=NL. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/11586130-000000000-00000","article-title":"Standardizing the inclusion of indirect medical costs in economic evaluations","volume":"29","author":"van Baal","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2017.05.013_bib40","unstructured":"Institute for Medical Technology Assessment. Practical Application to Include Disease Costs (PAID). Available from: www.imta.nl\/paid. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib41","unstructured":"National Institute for Public Health and Environment (RIVM). Heart failure: epidemiology, risk factors and future [in Dutch]. Available from: http:\/\/www.rivm.nl\/Documenten_en_publicaties\/Wetenschappelijk\/Rapporten\/2012\/maart\/Hartfalen_epidemiologie_risicofactoren_en_toekomst. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib42","unstructured":"Dutch national public health and health care (Volksgezondheidenzorg.info) figures & context, trends and future [in Dutch]. Available from: https:\/\/www.volksgezondheidenzorg.info\/onderwerp\/hartfalen\/cijfers-context\/trends. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib43","unstructured":"The National Health Care Institute (Zorginstituut Nederland). Position of left ventricular assist device (LVAD) as destination therapy in heart failure [in Dutch]. Available from: https:\/\/www.zorginstituutnederland.nl\/actueel\/nieuws\/2015\/permanent-steunhart-bij-hartfalen-in-basispakket.html. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib44","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ahj.2005.03.066","article-title":"Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function","volume":"151","author":"Ahmed","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.jval.2017.05.013_bib45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.hfc.2008.03.008","article-title":"Epidemiology of chronic kidney disease in heart failure","volume":"4","author":"Ahmed","year":"2008","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.jval.2017.05.013_bib46","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/00019053-200624110-00003","article-title":"Using value of information analysis to prioritise health research: some lessons from recent UK experience","volume":"24","author":"Claxton","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2017.05.013_bib47","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1177\/0272989X07302555","article-title":"Calculating partial expected value of perfect information via Monte-Carlo sampling algorithms","volume":"27","author":"Brennan","year":"2007","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2017.05.013_bib48","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0272989X12468616","article-title":"The role of value-of-information analysis in a health care research priority setting: a theoretical case study","volume":"33","author":"Corro","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2017.05.013_bib49","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1177\/0272989X09340585","article-title":"The half-cycle correction: banish rather than explain it","volume":"29","author":"Barendregt","year":"2009","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2017.05.013_bib50","unstructured":"Statistics Netherlands (CBS). Price index. Available from: http:\/\/statline.cbs.nl\/StatWeb\/publication\/?VW=T&DM=SLEN&PA=83131ENG&LA=EN. [Accessed November 19, 2016]."},{"key":"10.1016\/j.jval.2017.05.013_bib51","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/hec.4730040502","article-title":"Sensitivity analysis in economic evaluation: a review of published studies","volume":"4","author":"Briggs","year":"1995","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2017.05.013_bib52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hec.4730030206","article-title":"Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis","volume":"3","author":"Briggs","year":"1994","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2017.05.013_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1524-4733.2005.08101.x","article-title":"Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty","volume":"8","author":"Briggs","year":"2005","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2017.05.013_bib54","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1467-9868.2004.05304.x","article-title":"Probabilistic sensitivity analysis of complex models: a Bayesian approach","volume":"66","author":"Oakley","year":"2004","journal-title":"J Royal Stat Soc Series B Stat Methodol"},{"key":"10.1016\/j.jval.2017.05.013_bib55","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","article-title":"Handling uncertainty in cost-effectiveness models","volume":"17","author":"Briggs","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2017.05.013_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1524-4733.2005.08101.x","article-title":"Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty","volume":"8","author":"Briggs","year":"2005","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2017.05.013_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0272989X8500500205","article-title":"Probabilistic sensitivity analysis using Monte-Carlo simulation: a practical approach","volume":"5","author":"Doubilet","year":"1985","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2017.05.013_bib58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40273-012-0011-8","article-title":"Cost-effectiveness acceptability curves revisited","volume":"31","author":"Al","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2017.05.013_bib59","doi-asserted-by":"crossref","first-page":"A479","DOI":"10.1016\/j.jval.2016.09.769","article-title":"Estimating study costs for use in VOI, A study of Dutch publicly funded drug related research","volume":"19","author":"van Asselt","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2017.05.013_bib60","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301517302619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301517302619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T01:08:41Z","timestamp":1550106521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301517302619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1098301517302619"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2017.05.013","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril\/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2017.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}